Inhaled version of remdesivir tipped for COVID-19 treatment
Gilead is moving to make out-of-hospital products after the antiviral was shown to be moderately effective as an infusion
An inhaled version of remdesivir is being developed after trials run by its maker showed moderate effectiveness for the drug given by infusion in patients with COVID-19.
Easier-to-administer versions of the antiviral could be used outside of hospitals, say makers Gilead Sciences Inc that released unpublished trial results on Monday.
Their late-stage study of nearly 600 patients shows IV remdesivir provides a modest benefit for hospitalised patients with moderate COVID-19 compared with standard treatment.
Remdesivir is the only drug so far that has been shown to help patients with COVID-19.
